CervoMed Inc. filed a Form 8-K with the SEC on October 29, 2026, disclosing the publication of two peer-reviewed research articles related to neflamapimod as a potential treatment for dementia with Lewy bodies.

Key Highlights

  • Two publications: CervoMed disclosed the publication of two peer-reviewed research articles related to neflamapimod.
  • Disease focus: Both articles address neflamapimod as a potential treatment for dementia with Lewy bodies, according to the filing.
  • Journals named: The filing references publications in Alzheimer's Research & Therapy and Cells.
  • Regulation FD: The disclosure was made under Item 7.01 (Regulation FD) and Item 8.01 (Other Events) of the current report.
  • Furnished, not filed: The press release and related information are furnished and, per the filing, "shall not be deemed 'filed' for purposes of Section 18 of the Securities Exchange Act of 1934."
  • Signed by CFO: The report was signed by William Elder, Chief Financial Officer and General Counsel of CervoMed Inc.

CervoMed Discloses Peer-Reviewed Research on Neflamapimod for Lewy Body Dementia

CervoMed Inc. (NASDAQ:CRVO), a clinical-stage company based in Boston, Massachusetts, filed a current report on October 29, 2026, announcing that two peer-reviewed research articles related to its investigational compound neflamapimod have been published. The filing was made under Items 7.01 and 8.01 of Form 8-K, covering Regulation FD disclosure and other events, respectively.

According to the filing, the publications appear in Alzheimer's Research & Therapy and Cells, with the content of the first paragraph of the company's press release and the sections under those two journal headings incorporated by reference into Item 8.01. The press release, attached as Exhibit 99.1, was issued on the same date as the filing. The filing does not reproduce the scientific findings of either article within the body of the 8-K itself.

The filing specifies that the information furnished under Item 7.01 and in Exhibit 99.1 "shall not be deemed 'filed' for purposes of Section 18 of the Securities Exchange Act of 1934," meaning it is not subject to the liabilities of that section and is not automatically incorporated by reference into other filings unless expressly stated. The report was signed by William Elder in his capacity as Chief Financial Officer and General Counsel.

What Was Disclosed

CervoMed Inc. reported the publication of two peer-reviewed articles on neflamapimod as a potential treatment for dementia with Lewy bodies, furnishing a press release as Exhibit 99.1 and incorporating portions of it into Item 8.01 of the current report dated October 29, 2026.